Analysis
Use of randomised trials to decide when to monitor response to new treatment
BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39476.623611.25 (Published 14 February 2008) Cite this as: BMJ 2008;336:361
Data supplement
Appendix
Appendix
Files in this Data Supplement:
- Appendix - Appendix
Related articles
- Research Published: 24 June 2009; BMJ 338 doi:10.1136/bmj.b2266
- Clinical Review Published: 17 March 2005; BMJ 330 doi:10.1136/bmj.330.7492.644
- Research Published: 21 January 2011; BMJ 342 doi:10.1136/bmj.d12
- Editorial Published: 19 August 2010; BMJ 341 doi:10.1136/bmj.c4102
See more
- Scarlett McNally: Obesity is a community issue, not just an individual oneBMJ March 29, 2023, 380 p702; DOI: https://doi.org/10.1136/bmj.p702
- Cardiologists in Romania illegally reused cardiac devices taken from dead patients, prosecutors allegeBMJ March 10, 2023, 380 p575; DOI: https://doi.org/10.1136/bmj.p575
- Physical activity: WHO and OECD outline policy options for achieving recommended exercise levelsBMJ February 17, 2023, 380 p378; DOI: https://doi.org/10.1136/bmj.p378
- US task force calls for hypertension screening in all pregnanciesBMJ February 13, 2023, 380 p347; DOI: https://doi.org/10.1136/bmj.p347
- Eldryd Hugh Owen Parry: cardiologist who founded the Tropical Health and Education TrustBMJ February 03, 2023, 380 p283; DOI: https://doi.org/10.1136/bmj.p283
Cited by...
- Patterns and trends of potentially inappropriate high-density lipoprotein cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 to 2014: analysis of linked individual patient data from the Australian Medicare Benefits Schedule and Pharmaceutical Benefits Scheme
- Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data
- Monitoring Adherence to Medication by Measuring Change in Blood Pressure
- Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens: An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials
- How long should treatments be continued?
- Criteria for Scientific Evaluation of Novel Markers: A Perspective
- Lipid re-screening: what is the best measure and interval?
- Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data